Angiotensin-converting enzyme gene polymorphism may be a risk factor for COVID-19 clinical outcome

Order of Publishing in Issue: 
Volume :14
Issue :2
April, 2020 - June, 2020
Page No: 
Kalpana Panati[1], Surendranatha Reddy .E. C[2] and Venkata Ramireddy Narala[3,*]
[1]Department of Biotechnology, Government College for Men, Kadapa –516004, A.P, India
[2]Department of Genetics and Genomics, Yogi Vemana University, Kadapa – 516 005, A.P, Indi
[3]Department of Zoology, Yogi Vemana University, Kadapa – 516 005, A.P, India

Angiotensin-converting enzyme 1(ACE1) and ACE2 play a major role in regulation of blood pressure and electrolytic balance. They are known to express in epithelial cells of various tissues. SARS-CoV2 uses ACE2 as one of the receptors to enter into the host cells. Coronavirus infection associated decrease in the expression of ACE2 is known to associate with vasoconstriction, hypertension and other cardiovascular problems. Patients who are on ACE1 inhibitors show increased ACE2 expression, which is known to protect the lung from acute lung injury. ACE1 and ACE2 polymorphisms might be associated with the infectivity, severity and recovery from the COVID-19. Association studies of ACE gene polymorphisms in affected population may suggest the clinical outcome of the COVID-19.

Angiotensin-converting enzyme; polymorphism; COVID-19; spike protein.
PDF469.57 KB

To download full text articles and issues in PDF at no cost.All you have to do is fill out a brief registration form. It's easy and it's free. At any time, you may request removal of your contact information from our database.
Click here to Register | Click here if you have already registered

2018 ABAP Awards

Invitation for Nominations to 2019 ABAP Awards
The Association of Biotechnology and Pharmacy invites nominations for the following awards from the eligible talented people with proven track record and achievements on or before August 31, 2019 in the prescribed format.



Upcoming 0 events

  • No upcoming events available

User login